Navigation Links
Roches Arthritis Drug Successful in III Stage Trail

Roche Holding AG says that arthritis drug Actemra has proved successful in a phase III clinical study. Actemra helps relieve symptoms of rheumatoid arthritis in difficult-to-treat patients in a clinical study thus bringing it closer to regulatory approval.

The Radiate study was conducted over 24 weeks with 498 patients with difficult-to-treat RA. Actemra was given in combination with a standard treatment called methotrexate in patients who had an inadequate response to a relatively new type of drugs known as anti-tumor necrosis factor therapy, or anti-TNFs. The treatment showed a significant improvement in disease signs and symptoms.

Biologic Actemra (tocilizumab), a humanized monoclonal antibody works by a different mechanism than today's rheumatoid arthritis treatments. Actema is the first biologic to inhibit the interleukin-6, or Il-6, receptor. IL-6 is considered an important mediator of the acute inflammatory response.

Sufferers of rheumatoid arthritis, or RA, begin to experience progressive joint damage early in the disease. The disease differs from what is popularly known as arthritis, typically associated with age-related joint pain; RA is a far more serious inflammatory disease that leads to destruction of cartilage and bone, and can lead to disability.

Roche plans to file Actemra, developed by Japanese pharmaceutical company Chugai Pharmaceutical Co. which Roche controls, for regulatory approval in Europe and the U.S. by the end of 2007.

This is the third of five international late-stage trials that are investigating Actemra's efficacy and safety. Roche plans to release results from one more this year, while data from the fifth study will become available at a later date.


'"/>




Page: 1

Related medicine news :

1. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
2. Another ray of hope for Arthritis Sufferers
3. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
4. B Vitamin protects and lowers toxicity of Arthritis Drug
5. FDA Approves New Arthritis Drug, Bextra
6. Risk Of Developing Arthritis
7. Arthritis Drug May Cause Liver Damage
8. Arthritis drug can prolong life
9. New treatment for Rheumatoid Arthritis
10. Important cause of Arthritis
11. Personality Impacts Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... Olathe, KS (PRWEB) , ... April 28, 2017 ... ... system have typically been previously exposed to more adverse experiences than children in ... have experienced trauma such as abuse, neglect or other family challenges. While no ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: